STOCKHOLM, May 22, 2024
/PRNewswire/ -- SciBase Holding AB ("SciBase") (STO:
SCIB), a leading developer of augmented intelligence-based
solutions for skin disorders announced today that a
new clinical study has been published presenting the improvement
that the Nevisense provides over visual and dermoscopic evaluation
when clinical evaluations were done by German dermatologists. The
article named "Utilizing Data from Electrical Impedance
Spectroscopy Significantly Improves the Decision to Biopsy
Pigmented Skin Lesions Beyond Clinical Evaluation and
Dermoscopy" has been published in the journal "SKIN - The
journal of cutaneous medicine". The study included 151 German
Dermatologists making a total of 22.197 clinical biopsy decisions.
Nevisense was able to improve the rate of correct biopsy choice
even after dermoscopic evaluation. While dermoscopy worsened
diagnostic accuracy for benign lesions, Nevisense results were able
to significantly improve decision making for these lesions as well.
This study demonstrates the clinical utility of Nevisense
technology for improving melanoma diagnosis.
The article is available through the following
link: https://jofskin.org/index.php/skin/article/view/2789.
"This is a very important study and results for SciBase as it
quantifies the improvement in clinical decision-making possible
with Nevisense even compared to dermsocopy. In Germany dermoscopy is standard of care for
Dermatologists. The study showed that the addition of Nevisense
further improved dermatologists' clinical performance. This is
another publication that shows that Nevisense has a significant
role in the diagnostic process to correctly identify malignant
lesions in order to not miss any melanomas", says Pia Renaudin, CEO of SciBase.
For additional information, please contact:
Pia Renaudin, VD, tel. +46732069802,
e-mail: pia.renaudin@scibase.com
Certified Advisor (CA):
Vator Securities
Tel: +46 8 580 065 99
Email: ca@vatorsec.se
About SciBase
SciBase is a global medical technology company, specializing
in early detection and prevention in dermatology. SciBase develops
and commercializes Nevisense, a unique point-of-care platform that
combines AI (artificial intelligence) and advanced EIS technology
to elevate diagnostic accuracy, ensuring proactive skin health
management.
Our commitment is to minimize patient suffering, allowing
clinicians to improve and save lives through timely detection and
intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in
dermatological advancements.
The company has been on the Nasdaq First North Growth Market
exchange since June 2, 2015. Learn
more at www.scibase.com. All press releases and
financial reports can be found here:
http://investors.scibase.se/en/pressreleases.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/scibase/r/new-german-study-shows-nevisense-significantly-improves-dermatologists-clinical-decisions,c3986072
The following files are available for download:
https://mb.cision.com/Main/12371/3986072/2814254.pdf
|
PR_German Reader
Study
|
View original
content:https://www.prnewswire.co.uk/news-releases/new-german-study-shows-nevisense-significantly-improves-dermatologists-clinical-decisions-302152772.html